Literature DB >> 23616151

Improved hepatic lipid composition following short-term exercise in nonalcoholic fatty liver disease.

Jacob M Haus1, Thomas P J Solomon, Karen R Kelly, Ciaran E Fealy, Emily L Kullman, Amanda R Scelsi, Lan Lu, Mangesh R Pagadala, Arthur J McCullough, Chris A Flask, John P Kirwan.   

Abstract

CONTEXT: Hepatic steatosis, insulin resistance, inflammation, low levels of polyunsaturated lipids, and adiponectin are implicated in the development and progression of nonalcoholic fatty liver disease (NAFLD).
OBJECTIVE: We examined the effects of short-term aerobic exercise on these metabolic risk factors. DESIGN AND PARTICIPANTS: Obese individuals (N = 17, 34.3 ± 1.0 kg/m²) with clinically confirmed NAFLD were enrolled in a short-term aerobic exercise program that consisted of 7 consecutive days of treadmill walking at ~85% of maximal heart rate for 60 minutes per day. Preintervention and postintervention measures included hepatic triglyceride content, and a lipid saturation index and polyunsaturated lipid index (PUI) of the liver, obtained by (1)H magnetic resonance spectroscopy (N = 14). Insulin sensitivity was estimated from an oral glucose tolerance test (OGTT), and mononuclear cells were isolated to assess reactive oxygen species production during the OGTT. Circulating glucose, insulin, and high molecular weight (HMW) adiponectin were determined from plasma. MAIN OUTCOME: Short-term aerobic exercise training improved hepatic lipid composition in patients with NAFLD.
RESULTS: Exercise training resulted in an increase in liver PUI (P < .05), increased insulin sensitivity (Matsuda Index: P < .05), HMW adiponectin (P < .05), and maximal oxygen consumption (P < .05). Reactive oxygen species production during the OGTT was reduced following exercise training (P < .05). HMW adiponectin was increased after the exercise program and the increase was positively correlated with the increase in liver PUI (r = 0.52, P = .05). Body weight remained stable during the program (P > .05).
CONCLUSION: Short-term exercise can target hepatic lipid composition, which may reduce the risk of NAFLD progression. The improvement in hepatic lipid composition may be driven by adiponectin.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23616151      PMCID: PMC3701282          DOI: 10.1210/jc.2013-1229

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  39 in total

Review 1.  Benefits of lifestyle modification in NAFLD.

Authors:  Stephen A Harrison; Christopher Paul Day
Journal:  Gut       Date:  2007-10-02       Impact factor: 23.059

2.  Measurement of reactive oxygen species in whole blood and mononuclear cells using chemiluminescence.

Authors:  K Thusu; E Abdel-Rahman; P Dandona
Journal:  Methods Mol Biol       Date:  1998

3.  Adiponectin as an independent predictor of the presence and degree of hepatic steatosis in the Dallas Heart Study.

Authors:  Aslan T Turer; Jeffrey D Browning; Colby R Ayers; Sandeep R Das; Amit Khera; Gloria L Vega; Scott M Grundy; Philipp E Scherer
Journal:  J Clin Endocrinol Metab       Date:  2012-03-21       Impact factor: 5.958

4.  Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial.

Authors:  Claudia O Zein; Lisa M Yerian; Prema Gogate; Rocio Lopez; John P Kirwan; Ariel E Feldstein; Arthur J McCullough
Journal:  Hepatology       Date:  2011-08-24       Impact factor: 17.425

5.  Skeletal muscle substrate utilization during submaximal exercise in man: effect of endurance training.

Authors:  B Kiens; B Essen-Gustavsson; N J Christensen; B Saltin
Journal:  J Physiol       Date:  1993-09       Impact factor: 5.182

6.  MMP-9 activity is increased by adiponectin in primary human hepatocytes but even negatively correlates with serum adiponectin in a rodent model of non-alcoholic steatohepatitis.

Authors:  Josef Wanninger; Roland Walter; Sabrina Bauer; Kristina Eisinger; Andreas Schäffler; Christoph Dorn; Thomas S Weiss; Claus Hellerbrand; Christa Buechler
Journal:  Exp Mol Pathol       Date:  2011-07-21       Impact factor: 3.362

7.  Effects of a 1-year dietary intervention with n-3 polyunsaturated fatty acid-enriched olive oil on non-alcoholic fatty liver disease patients: a preliminary study.

Authors:  Francesco Sofi; Ilaria Giangrandi; Francesca Cesari; Ilaria Corsani; Rosanna Abbate; Gian Franco Gensini; Alessandro Casini
Journal:  Int J Food Sci Nutr       Date:  2010-05-13       Impact factor: 3.833

8.  Human aging is associated with altered TNF-alpha production during hyperglycemia and hyperinsulinemia.

Authors:  J P Kirwan; R K Krishnan; J A Weaver; L F Del Aguila; W J Evans
Journal:  Am J Physiol Endocrinol Metab       Date:  2001-12       Impact factor: 4.310

9.  Effects of 7 days of exercise training on insulin sensitivity and responsiveness in type 2 diabetes mellitus.

Authors:  John P Kirwan; Thomas P J Solomon; Daniel M Wojta; Myrlene A Staten; John O Holloszy
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-04-21       Impact factor: 4.310

10.  Exercise and Omega-3 Polyunsaturated Fatty Acid Supplementation for the Treatment of Hepatic Steatosis in Hyperphagic OLETF Rats.

Authors:  Sarah J Borengasser; R Scott Rector; Grace M Uptergrove; E Matthew Morris; James W Perfield; Frank W Booth; Kevin L Fritsche; Jamal A Ibdah; John P Thyfault
Journal:  J Nutr Metab       Date:  2011-09-12
View more
  23 in total

1.  Short-term aerobic exercise training improves gut peptide regulation in nonalcoholic fatty liver disease.

Authors:  Emily L Kullman; Karen R Kelly; Jacob M Haus; Ciaran E Fealy; Amanda R Scelsi; Mangesh R Pagadala; Chris A Flask; Arthur J McCullough; John P Kirwan
Journal:  J Appl Physiol (1985)       Date:  2016-03-31

Review 2.  Nonmedicinal interventions in nonalcoholic fatty liver disease.

Authors:  Manuela G Neuman; Radu M Nanau; Lawrence B Cohen
Journal:  Can J Gastroenterol Hepatol       Date:  2015 Jun-Jul

Review 3.  The Effects of Physical Exercise on Fatty Liver Disease.

Authors:  Dirk J van der Windt; Vikas Sud; Hongji Zhang; Allan Tsung; Hai Huang
Journal:  Gene Expr       Date:  2017-12-06

Review 4.  Exercise Combats Hepatic Steatosis: Potential Mechanisms and Clinical Implications.

Authors:  John P Thyfault; R Scott Rector
Journal:  Diabetes       Date:  2020-04       Impact factor: 9.461

5.  β-Hydroxybutyrate is reduced in humans with obesity-related NAFLD and displays a dose-dependent effect on skeletal muscle mitochondrial respiration in vitro.

Authors:  Jacob T Mey; Melissa L Erickson; Christopher L Axelrod; William T King; Chris A Flask; Arthur J McCullough; John P Kirwan
Journal:  Am J Physiol Endocrinol Metab       Date:  2020-05-12       Impact factor: 4.310

6.  Physical activity as a treatment of non-alcoholic fatty liver disease: A systematic review.

Authors:  Maureen Whitsett; Lisa B VanWagner
Journal:  World J Hepatol       Date:  2015-08-08

Review 7.  Innate Immune Cells in the Adipose Tissue in Health and Metabolic Disease.

Authors:  Zoi Michailidou; Mario Gomez-Salazar; Vasileia Ismini Alexaki
Journal:  J Innate Immun       Date:  2021-04-13       Impact factor: 7.349

8.  Exercise Training Rapidly Increases Hepatic Insulin Extraction in NAFLD.

Authors:  Adithya Hari; Ciaràn E Fealy; Christopher L Axelrod; Jacob M Haus; Chris A Flask; Arthur J McCullough; John P Kirwan
Journal:  Med Sci Sports Exerc       Date:  2020-07

9.  Exercise-induced improvements in liver fat and endothelial function are not sustained 12 months following cessation of exercise supervision in nonalcoholic fatty liver disease.

Authors:  C J A Pugh; V S Sprung; H Jones; P Richardson; F Shojaee-Moradie; A M Umpleby; D J Green; N T Cable; M I Trenell; G J Kemp; D J Cuthbertson
Journal:  Int J Obes (Lond)       Date:  2016-07-21       Impact factor: 5.095

Review 10.  Magnetic Resonance Spectroscopy of Hepatic Fat from Fundamental to Clinical Applications.

Authors:  Duanghathai Pasanta; Khin Thandar Htun; Jie Pan; Montree Tungjai; Siriprapa Kaewjaeng; Hongjoo Kim; Jakrapong Kaewkhao; Suchart Kothan
Journal:  Diagnostics (Basel)       Date:  2021-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.